Aquestive Therapeutics Secures $150M Debt Facility, Advances Anaphylm Resubmission
Event summary
- Aquestive Therapeutics secured a $150 million debt facility with Oaktree Capital Management, L.P., saving $45 million in principal payments over the next three years.
- The company reaffirmed its guidance to resubmit the Anaphylm™ NDA in Q3 2026, following alignment with the FDA on study designs.
- Aquestive completed a phase 1 study for AQST-108 in subjects with androgenic alopecia with no safety issues observed.
- Total revenues increased by 66% to $14.4 million in Q1 2026, driven by increases in license and royalty revenue and manufacture and supply revenue.
- The company expanded its planned field force to approximately 75 sales representatives, a 50% increase from prior guidance.
The big picture
Aquestive Therapeutics is positioning itself for a potential Anaphylm™ approval with strategic financial moves and regulatory alignment. The $150 million debt facility provides critical flexibility, while the expanded sales force and clinical progress on AQST-108 underscore the company’s focus on both immediate and long-term growth. The broader pharmaceutical industry is watching closely as Aquestive navigates the competitive landscape of allergy and dermatological treatments.
What we're watching
- Regulatory Approval
- The pace at which Aquestive can address FDA concerns and secure Anaphylm™ approval will determine its market entry timeline and competitive positioning.
- Financial Flexibility
- How Aquestive utilizes the $150 million debt facility to extend its cash runway and support commercial launch readiness for Anaphylm™, if approved.
- Pipeline Progress
- The potential of AQST-108 to address multiple dermatological conditions and its impact on Aquestive’s long-term growth strategy.
Related topics